Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | PDE3B | Q13370 | 16/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.64 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Siguazodan SCHEMBL5170622 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10652569 | 0.88 | KDM4E (0.66) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10762684 | 0.88 | KDM4E (0.66) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10653471 | 0.88 | KDM4E (0.66) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10651830 | 0.87 | KDM4E (0.67) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10765447 | 0.86 | KDM4E (0.64) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10764400 | 0.86 | KDM4E (0.64) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10618267 | 0.86 | KDM4E (0.76) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10764489 | 0.86 | KDM4E (0.63) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 | |
| SCHEMBL10652516 | 0.85 | KDM4E (0.62) | KDM4EALDH1A1CYP1A2CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176960-B1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-09-29 | — | — | EP | claimed |
| US-20240366620-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-11-07 | — | — | US | disclosed |
| EP-3334404-B1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A AND SLFN12 | BROAD INST INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-12053476-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-08-06 | — | — | US | disclosed |
| CN-108883112-B | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-07-26 | — | — | CN | disclosed |
| CN-114699528-A | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| CN-114601837-A | Compounds, compositions and methods for cancer patient stratification and cancer treatment | 拜耳医药股份公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-108366947-B | Compositions and methods for PDE3A or SLFN12 expressing cancers | 布罗德研究所股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220071995-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11207320-B2 | Compositions and methods for cancer expressing PDE3A or SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3411037-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | Bayer Pharma AG (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-20210236504-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-05 | — | — | US | disclosed |
| US-10966986-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-06 | — | — | US | disclosed |
| EP-3411037-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | Bayer Pharma Aktiengesellschaft (DE) | 2018-12-12 | — | — | EP | disclosed |
| US-20180235961-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| EP-3334404-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | The Broad Institute, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017134231-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017027854-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| EP-1176960-B1 | SYNERGISTIC COMBINATION COMPRISING ROFLUMILAST AND A PDE-3 INHIBITOR | ALTANA PHARMA AG (DE) | 2004-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236504-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | CREB1, CREBBP, SLFN12 | KDM4E 2202/4885ALDH1A1 591/4885CYP1A2 2987/4885 |
| US-10966986-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | SLFN12, CREB1, CREBBP | KDM4E 2614/4885ALDH1A1 592/4885CYP1A2 3446/4885 |
| US-20220071995-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | SMPD3, SMPD1, SMPD2 | KDM4E 2875/4885ALDH1A1 492/4885CYP1A2 839/4885 |
| US-20180235961-A1 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 | SMPD3, SMPD1, SMPD2 | KDM4E 2875/4885ALDH1A1 492/4885CYP1A2 839/4885 |
| US-12053476-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | CREB1, CREBBP, SLFN12 | KDM4E 2202/4885ALDH1A1 591/4885CYP1A2 2987/4885 |
| US-11207320-B2 | Compositions and methods for cancer expressing PDE3A or SLFN12 | SMPD3, SMPD1, SMPD2 | KDM4E 2875/4885ALDH1A1 492/4885CYP1A2 839/4885 |
| US-20240366620-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | CREB1, CREBBP, SLFN12 | KDM4E 2202/4885ALDH1A1 591/4885CYP1A2 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.